1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline
4. TECHNOLOGICAL OUTLOOK
5. ANTI-OBESITY DRUGS MARKET BY MECHANISM OF ACTION
5.1. Introduction
5.2. Peripherally Acting Drugs
5.3. Centrally Acting Drugs
6. ANTI-OBESITY DRUGS MARKET BY DRUG TYPE
6.1. Introduction
6.2. Prescription Drugs
6.3. OTC Drugs
7. ANTI-OBESITY DRUGS MARKET BY MODE OF ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Inectable
8. ANTI-OBESITY DRUGS MARKET BY END-USER
8.1. Introduction
8.2. Adults
8.3. Children & Youngsters
9. ANTI-OBESITY DRUGS MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. By Mechanism of Action
9.2.2. By Type
9.2.3. By Mode of Administration
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. USA
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Mechanism of Action
9.3.2. By Type
9.3.3. By Mode of Administration
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Mechanism of Action
9.4.2. By Type
9.4.3. By Mode of Administration
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. Germany
9.4.5.2. France
9.4.5.3. United Kingdom
9.4.5.4. Spain
9.4.5.5. Others
9.5. Middle East and Africa
9.5.1. By Mechanism of Action
9.5.2. By Type
9.5.3. By Mode of Administration
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. UAE
9.5.5.3. Israel
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. By Mechanism of Action
9.6.2. By Type
9.6.3. By Mode of Administration
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. China
9.6.5.2. India
9.6.5.3. Japan
9.6.5.4. South Korea
9.6.5.5. Indonesia
9.6.5.6. Thailand
9.6.5.7. Taiwan
9.6.5.8. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Currax Pharmaceuticals LLC
11.2. GlaxoSmithKline PLC
11.3. Novo Nordisk A/S
11.4. Pfizer Inc.
11.5. Eli Lilly and Company
11.6. VIVUS LLC
11.7. Boehringer Ingelheim International GmbH
11.8. AstraZeneca plc
11.9. Rhythm Pharmaceuticals Inc
11.10. Amgen Inc
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES